*All times listed are Central European Time (CET)
8:00 am Registration and Coffee
8:45 am Chair’s Opening Remarks
9:00 am Presentation from Our Partners at ABX-CRO and Oncodesign Taking Radiopharmaceuticals to their Next Evolutionary Level
9:55 am Presentation from our Partners at Radiopharm Theranostics
Synopsis
10:25 am Speed Networking & Refreshment Break
Drug Development
Drug Discovery & Radiopharmaceutical Innovation
11:30 am Pancreatic Cancer – Can We Overcome The Status Quo?
Synopsis
• Epidemiology and current state-of-the-art technology
• Towards personalised and accurate diagnostics of PDAC
• Status of radiotheranostic approach – from bench to bedside
12:00 pm New Life for Satoreotide – The Antagonist Moves On
Synopsis
• Update regarding satoreotide
• Antagonist vs agonist, SST2 receptor
• Neuroendocrine tumors
Advanced Preclinical Practices & Technology
1:30 pm Diagnostic Radioimmunocionjugate Targeting the Oxidized Macrophage Migration Inhibitory Factor (oxMIF)
Synopsis
• Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine consisting of three identical
subunits that drives tumorigenic cell signaling and exerts immunomodulatory activities in the tumor
microenvironment
• ON102 is a radioimmunoconjugate designed to provide a non-invasive approach for diagnostic applications
Phase 1 Development
2:00 pm Phase 1 Development of Radspherin
Synopsis
• Radspherin®, is a new alpha-emitting radioactive microsphere designed for treatment of metastatic cancers in body cavities
• Radspherin® has in animal models been shown to cause a reduction in tumour cell growth and a significant increased survival
Supply Chain, Infrastructure & Logistics
Radionuclide Generation & Stock Levels
11:30 am Presentation from our Partners at NRG – Field Lab
Synopsis
11:45 am Production & Availability of 211At: Near Term Steps Towards Global Access
Synopsis
• Current Status of 211At production and availability
• Future prospects for 211At
• Discussion of feasibility of commerically-compatible supply – any time soon?
12:15 pm Presentation from our Partners at Ionetix
Synopsis
Radionuclide Supply Chain Hurdles & Solutions
1:30 pm Building a Resilient Isotope Supply Chain for Clinical Trials
Synopsis
• Building a global clinical and isotope supply
• Effectively setting up clinical sites setup
• Building a nuclear regulatory strategy
2:00 pm Alpha Targeted Therapy & Environmental Impacts
Synopsis
• Alpha candidate and future needs
• Production situation
• Understanding and preparing for environmental impacts
2:30 pm Afternoon Coffee Break – Poster Session
Overcoming Clinical & Radioactive Compound Regulation
3:30 pm Panel Discussion: Perspectives on the State of EU & US Radiopharmaceutical Regulation
Synopsis
Panel of Industry Regulatory Staff, Clinicians, Radiopharmacists, Technologists and Regulatory Consultants to discuss how EU regulation has changed over the past year and what changes they are expecting in the coming 12 months:
• EMA regulation of radiopharmaceuticals and country-specific differences in radiopharmaceutical regulation
• Ripple effects from the FDA marketing approval of Pluvitco
• What can we educate the regulators on to help reform policy on RLT in the EU?